BriaCell Therapeutics Corp., based in Philadelphia, PA, specializes in developing targeted immunotherapies for advanced breast cancer and other cancers. As a publicly traded immuno-oncology company (Nasdaq: BCTX, BCTXW; TSX: BCT), it advances innovative cancer treatments with a growing investor and public following. Its focus on effective, targeted therapies positions it as a notable player in the oncology field.

‌